R&D The innovative future of CRISPR tech CRISPR-based therapies have moved from theory to reality, after the recent landmark approval of the first such treatment by the FDA.
News BARDA backs Locus phage therapy for resistant E coli The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in de
News NIH abandons trial of SIGA's mpox drug Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
